Adrien N Bernstein1, Jonathan E Shoag1, Ron Golan1, Joshua A Halpern1, Edward M Schaeffer2, Wei-Chun Hsu3, Paul L Nguyen4, Art Sedrakyan3, Ronald C Chen5, Scott E Eggener6, Jim C Hu7. 1. Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York. 2. Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 3. Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, New York. 4. Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 5. Department of Radiation Oncology, University of North Carolina, Chapel Hill, North Carolina. 6. Division of Urology, University of Chicago Medicine, Chicago, Illinois. 7. Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York. Electronic address: Jch9011@med.cornell.edu.
Abstract
PURPOSE: The incidence of localized prostate cancer has decreased with shifts in prostate cancer screening. While recent population based studies demonstrated a stable incidence of locoregional prostate cancer, they categorized organ confined, extraprostatic and lymph node positive disease together. However, to our knowledge the contemporary incidence of prostate cancer with pelvic lymph node metastases remains unknown. MATERIALS AND METHODS: We used SEER (Surveillance, Epidemiology and End Results) data from 2004 to 2014 to identify men diagnosed with prostate cancer. We analyzed trends in the age standardized prostate cancer incidence by stage. The impact of disease extent on mortality was assessed by adjusted Cox proportional hazard analysis. RESULTS: During the study period the annual incidence of nonmetastatic prostate cancer decreased from 5,119.1 to 2,931.9 per million men (IR 0.57, 95% CI 0.56-0.58, p <0.01) while the incidence of pelvic lymph node metastases increased from 54.1 to 79.5 per million men (IR 1.47, 95% CI 1.33-1.62, p <0.01). The incidence of distant metastases in men 75 years old or older reached a nadir in 2011 compared to 2004 (IR 0.81, 95% CI 0.74-0.90, p <0.01) and it increased in 2012 compared to 2011 (IR 1.13, 95% CI 1.02-1.24, p <0.05). The risk of cancer specific mortality significantly increased in men diagnosed with pelvic lymph node metastases (HR 4.5, 95% CI 4.2-4.9, p <0.01) and distant metastases (HR 21.9, 95% CI 21.2-22.7, p <0.01) compared to men with nonmetastatic disease. CONCLUSIONS: The incidence of pelvic lymph node metastases is increasing coincident with a decline in the detection of localized disease. Whether this portends an increase in the burden of advanced disease or simply reflects decreased lead time remains unclear. However, this should be monitored closely as the increase in N1 disease reflects an increase in incurable prostate cancer at diagnosis.
PURPOSE: The incidence of localized prostate cancer has decreased with shifts in prostate cancer screening. While recent population based studies demonstrated a stable incidence of locoregional prostate cancer, they categorized organ confined, extraprostatic and lymph node positive disease together. However, to our knowledge the contemporary incidence of prostate cancer with pelvic lymph node metastases remains unknown. MATERIALS AND METHODS: We used SEER (Surveillance, Epidemiology and End Results) data from 2004 to 2014 to identify men diagnosed with prostate cancer. We analyzed trends in the age standardized prostate cancer incidence by stage. The impact of disease extent on mortality was assessed by adjusted Cox proportional hazard analysis. RESULTS: During the study period the annual incidence of nonmetastatic prostate cancer decreased from 5,119.1 to 2,931.9 per million men (IR 0.57, 95% CI 0.56-0.58, p <0.01) while the incidence of pelvic lymph node metastases increased from 54.1 to 79.5 per million men (IR 1.47, 95% CI 1.33-1.62, p <0.01). The incidence of distant metastases in men 75 years old or older reached a nadir in 2011 compared to 2004 (IR 0.81, 95% CI 0.74-0.90, p <0.01) and it increased in 2012 compared to 2011 (IR 1.13, 95% CI 1.02-1.24, p <0.05). The risk of cancer specific mortality significantly increased in men diagnosed with pelvic lymph node metastases (HR 4.5, 95% CI 4.2-4.9, p <0.01) and distant metastases (HR 21.9, 95% CI 21.2-22.7, p <0.01) compared to men with nonmetastatic disease. CONCLUSIONS: The incidence of pelvic lymph node metastases is increasing coincident with a decline in the detection of localized disease. Whether this portends an increase in the burden of advanced disease or simply reflects decreased lead time remains unclear. However, this should be monitored closely as the increase in N1 disease reflects an increase in incurable prostate cancer at diagnosis.
Authors: G Gandaglia; Q-D Trinh; J C Hu; J Schiffmann; A Becker; F Roghmann; I Popa; Z Tian; P Perrotte; F Montorsi; A Briganti; P I Karakiewicz; M Sun; F Abdollah Journal: Eur J Surg Oncol Date: 2014-01-02 Impact factor: 4.424
Authors: Carlotta Buzzoni; Anssi Auvinen; Monique J Roobol; Sigrid Carlsson; Sue M Moss; Donella Puliti; Harry J de Koning; Chris H Bangma; Louis J Denis; Maciej Kwiatkowski; Marcos Lujan; Vera Nelen; Alvaro Paez; Marco Randazzo; Xavier Rebillard; Teuvo L J Tammela; Arnauld Villers; Jonas Hugosson; Fritz H Schröder; Marco Zappa Journal: Eur Urol Date: 2015-03-16 Impact factor: 20.096
Authors: Jim C Hu; Sandip M Prasad; Xiangmei Gu; Stephen B Williams; Stuart R Lipsitz; Paul L Nguyen; Toni K Choueiri; Wesley W Choi; Anthony V D'Amico Journal: Urology Date: 2010-08-16 Impact factor: 2.649
Authors: Nancy L Keating; Pang-Hsiang Liu; A James O'Malley; Stephen J Freedland; Matthew R Smith Journal: Eur Urol Date: 2013-02-22 Impact factor: 20.096
Authors: Stephen J Freedland; William J Aronson; Christopher J Kane; Joseph C Presti; Christopher L Amling; David Elashoff; Martha K Terris Journal: J Clin Oncol Date: 2003-12-22 Impact factor: 44.544
Authors: Saira Khan; Sanah Vohra; Laura Farnan; Shekinah N C Elmore; Khadijah Toumbou; Madhav K C; Elizabeth T H Fontham; Edward S Peters; James L Mohler; Jeannette T Bensen Journal: Prostate Date: 2022-07-26 Impact factor: 4.012
Authors: Daniela A Ferraro; Urs J Muehlematter; Helena I Garcia Schüler; Niels J Rupp; Martin Huellner; Michael Messerli; Jan Hendrik Rüschoff; Edwin E G W Ter Voert; Thomas Hermanns; Irene A Burger Journal: Eur J Nucl Med Mol Imaging Date: 2019-09-14 Impact factor: 9.236
Authors: Simona Malaspina; Mikael Anttinen; Pekka Taimen; Ivan Jambor; Minna Sandell; Irina Rinta-Kiikka; Sami Kajander; Jukka Schildt; Ekaterina Saukko; Tommi Noponen; Jani Saunavaara; Peter B Dean; Roberto Blanco Sequeiros; Hannu J Aronen; Jukka Kemppainen; Marko Seppänen; Peter J Boström; Otto Ettala Journal: Eur J Nucl Med Mol Imaging Date: 2021-03-13 Impact factor: 9.236
Authors: Juho Jasu; Teemu Tolonen; Emmanuel S Antonarakis; Himisha Beltran; Susan Halabi; Mario A Eisenberger; Michael A Carducci; Yohann Loriot; Kim Van der Eecken; Martijn Lolkema; Charles J Ryan; Sinja Taavitsainen; Silke Gillessen; Gunilla Högnäs; Timo Talvitie; Robert J Taylor; Antti Koskenalho; Piet Ost; Teemu J Murtola; Irina Rinta-Kiikka; Teuvo Tammela; Anssi Auvinen; Paula Kujala; Thomas J Smith; Pirkko-Liisa Kellokumpu-Lehtinen; William B Isaacs; Matti Nykter; Juha Kesseli; G Steven Bova Journal: Eur Urol Open Sci Date: 2021-07-02